Cantor Fitzgerald Maintains Overweight on VolitionRX, Raises Price Target to $2.5
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has maintained an Overweight rating on VolitionRX (AMEX:VNRX) and increased the price target from $2.1 to $2.5.
November 16, 2023 | 2:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Ross Osborn reaffirmed an Overweight rating on VolitionRX and raised the price target to $2.5, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically suggests a bullish view on the stock's future performance. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100